The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems.
Diagnosis
Health care costs
Rare diseases
Utilization
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
22 10 2021
22 10 2021
Historique:
received:
17
05
2021
accepted:
30
09
2021
entrez:
22
10
2021
pubmed:
23
10
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Rare diseases (RD) are a diverse collection of more than 7-10,000 different disorders, most of which affect a small number of people per disease. Because of their rarity and fragmentation of patients across thousands of different disorders, the medical needs of RD patients are not well recognized or quantified in healthcare systems (HCS). We performed a pilot IDeaS study, where we attempted to quantify the number of RD patients and the direct medical costs of 14 representative RD within 4 different HCS databases and performed a preliminary analysis of the diagnostic journey for selected RD patients. The overall findings were notable for: (1) RD patients are difficult to quantify in HCS using ICD coding search criteria, which likely results in under-counting and under-estimation of their true impact to HCS; (2) per patient direct medical costs of RD are high, estimated to be around three-fivefold higher than age-matched controls; and (3) preliminary evidence shows that diagnostic journeys are likely prolonged in many patients, and may result in progressive, irreversible, and costly complications of their disease CONCLUSIONS: The results of this small pilot suggest that RD have high medical burdens to patients and HCS, and collectively represent a major impact to the public health. Machine-learning strategies applied to HCS databases and medical records using sentinel disease and patient characteristics may hold promise for faster and more accurate diagnosis for many RD patients and should be explored to help address the high unmet medical needs of RD patients.
Sections du résumé
BACKGROUND
Rare diseases (RD) are a diverse collection of more than 7-10,000 different disorders, most of which affect a small number of people per disease. Because of their rarity and fragmentation of patients across thousands of different disorders, the medical needs of RD patients are not well recognized or quantified in healthcare systems (HCS).
METHODOLOGY
We performed a pilot IDeaS study, where we attempted to quantify the number of RD patients and the direct medical costs of 14 representative RD within 4 different HCS databases and performed a preliminary analysis of the diagnostic journey for selected RD patients.
RESULTS
The overall findings were notable for: (1) RD patients are difficult to quantify in HCS using ICD coding search criteria, which likely results in under-counting and under-estimation of their true impact to HCS; (2) per patient direct medical costs of RD are high, estimated to be around three-fivefold higher than age-matched controls; and (3) preliminary evidence shows that diagnostic journeys are likely prolonged in many patients, and may result in progressive, irreversible, and costly complications of their disease CONCLUSIONS: The results of this small pilot suggest that RD have high medical burdens to patients and HCS, and collectively represent a major impact to the public health. Machine-learning strategies applied to HCS databases and medical records using sentinel disease and patient characteristics may hold promise for faster and more accurate diagnosis for many RD patients and should be explored to help address the high unmet medical needs of RD patients.
Identifiants
pubmed: 34674728
doi: 10.1186/s13023-021-02061-3
pii: 10.1186/s13023-021-02061-3
pmc: PMC8532301
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
429Informations de copyright
© 2021. The Author(s).
Références
J Biomed Semantics. 2020 Nov 12;11(1):13
pubmed: 33183351
Orphanet J Rare Dis. 2016 Mar 24;11:30
pubmed: 27012247
Genet Med. 2017 May;19(5):546-552
pubmed: 27657686
Science. 2013 Aug 23;341(6148):1233158
pubmed: 23845948
Seizure. 2019 Oct;71:295-303
pubmed: 31518880
Genet Med. 2019 Feb;21(2):269-271
pubmed: 30100610
Health Policy. 2019 Nov;123(11):1049-1052
pubmed: 31506190
PLoS One. 2020 Jul 2;15(7):e0235574
pubmed: 32614911
Orphanet J Rare Dis. 2018 Nov 12;13(1):202
pubmed: 30419920
Am J Med Genet C Semin Med Genet. 2018 Dec;178(4):458-463
pubmed: 30580481
Pharmacoeconomics. 2020 Nov;38(11):1219-1236
pubmed: 32812149
Health Policy. 2015 Jul;119(7):964-79
pubmed: 25661982
Am J Manag Care. 2020 Aug;26(8 Suppl):S177-S183
pubmed: 32840331
Cell. 2019 Mar 21;177(1):32-37
pubmed: 30901545
Inquiry. 2019 Jan-Dec;56:46958019880696
pubmed: 31583928
Genet Med. 2021 Jun 28;:
pubmed: 34183788
Health Aff (Millwood). 2018 May;37(5):773-779
pubmed: 29733727
J Genet Couns. 2019 Dec;28(6):1107-1118
pubmed: 31478310
NPJ Genom Med. 2018 Apr 4;3:10
pubmed: 29644095
N Engl J Med. 2017 Nov 2;377(18):1723-1732
pubmed: 29091570
Curr Med Chem. 2017;24(29):3153-3158
pubmed: 28494745
Eur J Hum Genet. 2020 Feb;28(2):165-173
pubmed: 31527858
Orphanet J Rare Dis. 2017 Apr 26;12(1):79
pubmed: 28446219
Orphanet J Rare Dis. 2020 Nov 4;15(1):311
pubmed: 33148291
Epilepsy Behav. 2019 Apr;93:65-72
pubmed: 30831405
JAMIA Open. 2020 Sep 11;3(3):472-486
pubmed: 33426479
JAMA Netw Open. 2020 Sep 1;3(9):e2018109
pubmed: 32960281
Mol Genet Metab. 2013 Sep-Oct;110(1-2):179-80
pubmed: 23972786
Nat Rev Drug Discov. 2020 Feb;19(2):77-78
pubmed: 32020066